PDF file: 441-1448_Health_Canadas_review_of_Pfizer_docs.pdf
OPQ ID: 441-1448
Session: 441
Question number: Q-1448
Sessional paper: Q-1448
Title: Health Canada's review of Pfizer docs
Short description: 
Topic: vaccines
Identified concern: 
Keywords: 
Agencies: HC, PHAC
Date asked: 2023-04-25
Date tabled: 
Submitted by: Mr. Carrie (Oshawa)
Reply by: Minister of Health
Responded by: Mr. van Koeverden
Pages: 7
Status: not processed
Alert: yellow
Questions asked: 8
Questions answered: 1
Percent responded: 12%
Referenced sources: Canada.ca
Referenced links: https://covidvaccine.canada.ca/comirnaty/product-details, https://bit.ly/3w72x1y, https://covid-vaccine.canada.ca/, https://recalls-rappels.canada.ca/, https://clinical-information.canada.ca/search/ci-rc.After, https://health-infobase.canada.ca/covid-19/vaccine-safety
Official link: https://www.google.com/search?q=Q-1448+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-1448_Health_Canadas_review_of_Pfizer_docs.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-1448.txt
Original filename: Q-1448 (ORDER), Health Canada's review of Pfizer docs.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-1448 (ORDER), Health Canada's review of Pfizer docs.pdf
Machine extracted at: 2026-06-30 12:58:13

References / links:
- https://covidvaccine.canada.ca/comirnaty/product-details
- https://bit.ly/3w72x1y
- https://covid-vaccine.canada.ca/
- https://recalls-rappels.canada.ca/
- https://clinical-information.canada.ca/search/ci-rc.After
- https://health-infobase.canada.ca/covid-19/vaccine-safety
- Canada.ca

Machine notes:
(none)

Question text preview:
With regard to the Public Health Agency of Canada (PHAC) and Health Canada (HC): (a) did PHAC or HC receive or become aware of documents related to Pfizer-BioNTech which were the subject of a court order requiring their release to the public starting around January 6,
2022;
(b) if the answer to (a) is affirmative, (i) when did the government receive them, (ii) which department or agency reviewed them, (iii) what conclusions and recommendations were arrived at, (iv) was a risk versus benefit analysis conducted after the review, and, if so, what were the findings, (v) when did the review commence and finish;
(c) did PHAC or HC receive or become aware of the document titled: “5.3.6
CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED
THROUGH 28-FEB-2021”, and, if so, (i) on what date did PHAC or HC review the document, (ii) what were the conclusions and recommendations that resulted from the review of the document, (iii) when did the review commence and finish, (iv) which Canadian federal health agency was assigned to review this document and when;
(d) what are PHAC’s and HC’s latest warnings or instructions to health care professionals who advise Canadians about the Pfizer-BioNTech COVID-19 vaccine;
(e) do the warnings or instructions in (d) consider the adverse events of special interest identified in the Pfizer study; and (f) will the government notify Canadians about the events in (d)?